SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give an oral presentation and multiple poster presentations at the 21st Immunology of Diabetes Society (IDS) Congress being held April 20-24, 2026, in Brisbane, Australia. Data to be presented will highlight SAB BIO's lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for newly diagnosed Stage 3 T1D patients.